Cardiac Valve Global Market Report 2024

Cardiac valves are artificial devices designed to regulate the flow of blood within the heart, ensuring unidirectional blood movement from the heart to other parts of the body. These implantable devices play a crucial role in replacing damaged valves that may have ceased functioning due to various diseases. The primary objective of cardiac valves is to maintain the proper flow of blood through the heart and into the major blood vessels connected to it.

The primary types of cardiac valves include tissue valves, transcatheter valves, mechanical valves, and other variations. Tissue heart valves, utilized in open-heart or minimally invasive surgeries, aim to prevent blood clot formation inside the vessels. These valves are crafted from durable and flexible animal tissue obtained from donors and are employed in cardiac valve repair and replacement procedures. Various positions in the heart, such as the aortic valve and mitral valve, necessitate the repair or replacement of cardiac valves. End-users of cardiac valves include hospitals, clinics, specialty centers, cardiac research institutes, and other healthcare facilities.

The cardiac valve market research report is one of a series of new reports that provides cardiac valve market statistics, including cardiac valve industry global market size, regional shares, competitors with a cardiac valve market share, detailed cardiac valve market segments, market trends and opportunities, and any further data you may need to thrive in the cardiac valve industry. This cardiac valve market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The cardiac valve market size has grown rapidly in recent years. It will grow from $9.68 billion in 2023 to $11.17 billion in 2024 at a compound annual growth rate (CAGR) of 15.3%. The historical growth of cardiac valves can be attributed to factors such as an aging population leading to an increased incidence of valvular heart disease, a rise in the prevalence of risk factors like obesity and hypertension, advancements in diagnostic and imaging technologies for detecting valve diseases, awareness campaigns and educational initiatives focusing on heart health and valve disease, and the development of minimally invasive and transcatheter valve procedures.

The cardiac valve market size is expected to see rapid growth in the next few years. It will grow to $18.87 billion in 2028 at a compound annual growth rate (CAGR) of 14.0%. The forecasted growth in the cardiac valves market can be attributed to the increasing demand for bioengineered and tissue-engineered heart valves, the aging global population leading to a higher prevalence of valve diseases, the adoption of telemedicine and remote patient monitoring for individuals with valve conditions, advancements in surgical techniques including robotics-assisted valve procedures, and the utilization of 3D printing for personalized heart valve manufacturing. Major trends in the forecast period include continuous advancements in valve replacement and repair techniques, the integration of artificial intelligence (AI) for valve disease detection and treatment planning, and the widespread adoption of 3D printing for personalized heart valve manufacturing.

The increasing prevalence of cardiovascular diseases is poised to drive the growth of the cardiac valve market. Factors such as smoking, obesity, lack of physical activity, and other cardiovascular stressors contribute to a gradual rise in cardiovascular diseases. Coronary artery disease, characterized by the build-up of fatty plaques in arteries, is a common cause. This surge in heart-related ailments has heightened the demand for cardiac valves to address heart valve issues. As of September 2023, data from the World Health Organization indicates that cardiovascular diseases account for a substantial portion, approximately 74%, of global deaths related to non-communicable diseases (NCDs) or chronic conditions.

The expansion of the cardiac valves market is expected to be fueled by the increasing healthcare expenditure. Healthcare expenditure, encompassing costs associated with healthcare goods and services, is a critical factor supporting the development and accessibility of cardiac valves. In November 2022, the Canadian Institute for Health Information reported a rise in healthcare expenditure to 0.8%, amounting to $331 billion in 2022, compared to 7.6% in 2021. This upward trend in healthcare spending is a significant driver of the growth observed in the cardiac valves market.

A notable trend in the cardiac valve market is the integration of technological advancements. Major players in the industry are focusing on innovative technologies such as neochordae implantation, annuloplasty ring, and robotic surgery to enhance their market presence. These technological advancements contribute to less invasive treatment options for heart diseases, offering patients protection against life-threatening conditions such as heart stroke and cardiac arrest. In September 2022, Edwards, a leading US-based medical technology company, introduced the Sapien 3 Ultra Resilia transcatheter heart valve featuring anti-calcification technology. This technology platform was designed to irreversibly block calcium binding sites in bioprosthetic valves.

Major companies within the cardiac valves market are actively engaged in the development of innovative products, exemplified by the introduction of next-generation transcatheter aortic valve implantation (TAVI) systems to drive market revenues. Abbott, a prominent US-based medical device company, launched the Navitor TAVI system in December 2022. This self-expanding valve is designed to treat patients with symptomatic severe native aortic stenosis deemed at high or extreme risk for open-heart surgery. The Navitor TAVI system incorporates intelligent design features, including the smart PVL-sealing NaviSeal Cuff, stable and accurate placement, exceptional single-digit gradients, and uncompromised small vessel access, catering to a broad spectrum of routine to challenging anatomies.

In January 2022, Venus Medtech, a China-based company specializing in structural heart disease treatment, completed the acquisition of Cardiovalve Ltd., an Israel-based medical device company focused on developing a transfemoral mitral valve replacement system. This strategic move enables Venus Medtech to advance clinical research in Europe and the United States while accelerating clinical development and commercialization in China. The acquisition positions Venus Medtech as China's most comprehensive platform for treating mitral and tricuspid regurgitation.

Major companies operating in the cardiac valve market include LivaNova PLC, Abbott Laboratories, Colibri Heart Valve LLC, TTK HealthCare Limited, Artivion Inc., Edwards Lifesciences Corporation, Boston Scientific Corporation, Symetis SA, Jenavalve Technology Inc., CryoLife Inc., Lepu Medical Technology Co. Ltd., Braile Biomedical, Sorin Group, Micro Interventional Devices Inc., Medtronic Inc., Lepu Medical Technology, Edward Lifesciences Corporation, Neovasc Inc., Xeltis AG, JenaValve Technology, Braile Biomédica Ltd., Medtronic PLC, Meril Life Sciences Pvt. Ltd., Auto Tissue Berlin GmbH, On-X Life Technologies Inc., Thubrikar Aortic Valve Inc., LifeNet Health Inc.

North America was the largest region in the cardiac valve market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cardiac valve market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

The countries covered in the cardiac valve market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK and USA.

The cardiac valve market consists of sales of tricuspid valves and pulmonary valves. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.